Thousands of men suffering from prostate cancer are set to gain access to a life-extending drug on the NHS following a significant expansion of eligibility criteria.
Previously, the hormone therapy abiraterone, which functions by inhibiting testosterone production throughout the body, was only available to patients whose cancer had already spread.
